Skip to main content
. Author manuscript; available in PMC: 2010 Mar 25.
Published in final edited form as: Nature. 2010 Jan 7;463(7277):88–92. doi: 10.1038/nature08638

Figure 4. Therapeutic strategies to target chronic active BCR signaling.

Figure 4

A. Viability of DLBCL lines assessed by MTT assay after 4 days of treatment with varying doses of dasatinib, the BTK inhibitor PCI-32765 (compound 13 in ref.25), or an IKKβ inhibitor27. B. Effect of dasatinib on phospho-protein levels in ABC DLBCL cells. Three ABC DLBCL lines were treated with dasatinib (50 nM) for the indicated times and analyzed by Western blotting.